The price of Zymeworks BC Inc (NASDAQ: ZYME) closed at $9.88 in the last session, down -6.08% from day before closing price of $10.52. In other words, the price has decreased by -$0.64 from its previous closing price. On the day, 744321 shares were traded.
Ratios:
We take a closer look at ZYME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.41 and its Current Ratio is at 7.41. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On January 04, 2023, H.C. Wainwright reiterated its Neutral rating and also upped its target price recommendation from $10 to $8.
Jefferies Upgraded its Hold to Buy on December 20, 2022, whereas the target price for the stock was revised from $7.70 to $11.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 08 ’24 when Galbraith Kenneth sold 5,706 shares for $11.22 per share. The transaction valued at 63,996 led to the insider holds 23,762 shares of the business.
Moore Paul Andrew sold 2,339 shares of ZYME for $26,233 on Jan 08 ’24. The Chief Scientific Officer now owns 7,367 shares after completing the transaction at $11.22 per share. On Jan 08 ’24, another insider, Astle Christopher, who serves as the SVP & Chief Financial Officer of the company, sold 1,431 shares for $11.22 each. As a result, the insider received 16,050 and left with 6,503 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 695.80M and an Enterprise Value of 348.20M. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.26 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 4.58 whereas that against EBITDA is -2.88.
Stock Price History:
Over the past 52 weeks, ZYME has reached a high of $13.14, while it has fallen to a 52-week low of $6.01. The 50-Day Moving Average of the stock is 11.16, while the 200-Day Moving Average is calculated to be 8.76.
Shares Statistics:
According to the various share statistics, ZYME traded on average about 568.46K shares per day over the past 3-months and 612.69k shares per day over the past 10 days. A total of 70.12M shares are outstanding, with a floating share count of 65.91M. Insiders hold about 7.46% of the company’s shares, while institutions hold 92.57% stake in the company. Shares short for ZYME as of Mar 15, 2024 were 3.96M with a Short Ratio of 6.96, compared to 3.26M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.61% and a Short% of Float of 6.37%.
Earnings Estimates
The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.29 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.42, while EPS last year was -$0.36. The consensus estimate for the next quarter is -$0.08, with high estimates of $1.38 and low estimates of -$0.53.
Analysts are recommending an EPS of between -$0.24 and -$2.34 for the fiscal current year, implying an average EPS of -$1.04. EPS for the following year is -$0.78, with 6 analysts recommending between $0.88 and -$2.35.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $17.51M. It ranges from a high estimate of $35M to a low estimate of $5.2M. As of the current estimate, Zymeworks BC Inc’s year-ago sales were $35.58M, an estimated decrease of -50.80% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $33.97M, an increase of 174.80% over than the figure of -$50.80% in the same quarter last year. There is a high estimate of $135.2M for the next quarter, whereas the lowest estimate is $7M.
A total of 7 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $165M, while the lowest revenue estimate was $25M, resulting in an average revenue estimate of $95.04M. In the same quarter a year ago, actual revenue was $76.01M, up 25.00% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $122.26M in the next fiscal year. The high estimate is $272.15M and the low estimate is $30M. The average revenue growth estimate for next year is up 28.60% from the average revenue estimate for this year.
